Aztreonam

Antibiotic

Phase of research

FDA-/EMA-approved for Cystic Fibrosis

How it helps

Anti-Infective

General information

Aztreonam is an antibiotic. It was approved in the USA in 1986 for medical use and sold under the name e.g., Cayston®. It is used to treat infections caused by gram-negative bacteria, such as Pseudomonas aeruginosa. Nebulized forms of aztreonam are used to treat infections connected with cystic fibrosis. In relation to cystic fibrosis, our AIM tool found the data that aztreonam can improve respiratory symptoms and pulmonary function of patients. 

Aztreonam on PubChem
Aztreonam on DrugBank
Aztreonam on Wikipedia

Synonyms

AZLI, aztreonam lysinate, aztreonam lysine

Marketed as

Dietary sources

N/A

Structure not available

C19H31N7O10S2

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
General effect
6 5.76
Link Tested on Impact factor Notes
The effects of inhaled aztreonam on the cystic fibrosis lung microbiome humans 9.13
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. humans 9.79 Tested in combination with tobramycin.
An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. humans 2.24
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. humans 6.36
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. humans 3.19
Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. humans 3.85

Does not treat

Mutation Number of sources Average impact factor